Prophylactic Vancomycin — Competitive Intelligence Brief

Prophylactic Vancomycin (Prophylactic Vancomycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Oncology / Infectious Disease Prevention.

phase 3 Glycopeptide antibiotic Bacterial peptidoglycan D-Ala-D-Ala precursors Oncology / Infectious Disease Prevention Small molecule

Target snapshot

Prophylactic Vancomycin (Prophylactic Vancomycin) — Memorial Sloan Kettering Cancer Center. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prophylactic Vancomycin TARGET	Prophylactic Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan D-Ala-D-Ala precursors
Vancomycin IV	Vancomycin IV	Debiopharm International SA	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Cefazolin / Vancomycin	Cefazolin / Vancomycin	University of Cincinnati	marketed	Beta-lactam antibiotic / Glycopeptide antibiotic	Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors
Vancomycin antimicrobial-lock solution	Vancomycin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial cell wall (peptidoglycan precursors)
Oritavancin Injection	Oritavancin Injection	University of Pennsylvania	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
Vancomycin intermittent dosing interval	Vancomycin intermittent dosing interval	Massachusetts General Hospital	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Vancomycin with Taper/Pulse	Vancomycin with Taper/Pulse	VA Office of Research and Development	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class